Compare ERIC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERIC | RMD |
|---|---|---|
| Founded | 1876 | 1989 |
| Country | Sweden | United States |
| Employees | 89898 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8B | 36.8B |
| IPO Year | N/A | N/A |
| Metric | ERIC | RMD |
|---|---|---|
| Price | $11.40 | $232.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $10.40 | ★ $293.70 |
| AVG Volume (30 Days) | ★ 6.1M | 880.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.70% | 1.00% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.64 |
| Revenue Next Year | $1.46 | $7.38 |
| P/E Ratio | ★ $12.13 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.96 | $199.92 |
| 52 Week High | $11.64 | $293.81 |
| Indicator | ERIC | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 30.76 |
| Support Level | $9.37 | N/A |
| Resistance Level | $11.64 | $259.37 |
| Average True Range (ATR) | 0.26 | 5.62 |
| MACD | -0.04 | -2.38 |
| Stochastic Oscillator | 69.54 | 5.87 |
Ericsson provides telecom equipment and services that are primarily used to build and operate mobile networks. The firm divides its business into three segments: networks, cloud and software services, and enterprise. Wireless carriers have traditionally been the firm's primary customers, but it is pushing to cater more to enterprises as well, as both try to take advantage of 5G capabilities and utilize "as-a-service" communications platforms. The company also licenses its patents to handset manufacturers.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.